Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus Nivolumab in pMMR/MSS Colorectal Cancer
NCT04126733Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, nivolumab in colorectal cancer (CRC), sponsored by Bayer. Started Oct 2019; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04126733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126733.